Open-label trial and randomized, double-blind, placebo-controlled, crossover trial of hydrogen-enriched water for mitochondrial and inflammatory myopathies by Ito, Mikako et al.
RESEARCH Open Access
Open-label trial and randomized, double-blind,
placebo-controlled, crossover trial of hydrogen-
enriched water for mitochondrial and
inflammatory myopathies
Mikako Ito
1†, Tohru Ibi
2†, Ko Sahashi
3, Masashi Ichihara
4, Masafumi Ito
5 and Kinji Ohno
1*
Abstract
Background: Molecular hydrogen has prominent effects on more than 30 animal models especially of oxidative
stress-mediated diseases and inflammatory diseases. In addition, hydrogen effects on humans have been reported
in diabetes mellitus type 2, hemodialysis, metabolic syndrome, radiotherapy for liver cancer, and brain stem
infarction. Hydrogen effects are ascribed to specific radical-scavenging activities that eliminate hydroxyl radical and
peroxynitrite, and also to signal-modulating activities, but the detailed molecular mechanisms still remain elusive.
Hydrogen is a safe molecule that is largely produced by intestinal bacteria in rodents and humans, and no adverse
effects have been documented.
Methods: We performed open-label trial of drinking 1.0 liter per day of hydrogen-enriched water for 12 weeks in
five patients with progressive muscular dystrophy (PMD), four patients with polymyositis/dermatomyositis (PM/DM),
and five patients with mitochondrial myopathies (MM), and measured 18 serum parameters as well as urinary 8-
isoprostane every 4 weeks. We next conducted randomized, double-blind, placebo-controlled, crossover trial of 0.5
liter per day of hydrogen-enriched water or placebo water for 8 weeks in 10 patients with DM and 12 patients
with MM, and measured 18 serum parameters every 4 weeks.
Results: In the open-label trial, no objective improvement or worsening of clinical symptoms was observed. We,
however, observed significant effects in lactate-to-pyruvate ratios in PMD and MM, fasting blood glucose in PMD,
serum matrix metalloproteinase-3 (MMP3) in PM/DM, and serum triglycerides in PM/DM. In the double-blind trial,
no objective clinical effects were observed, but a significant improvement was detected in lactate in MM. Lactate-
to-pyruvate ratios in MM and MMP3 in DM also exhibited favorable responses but without statistical significance.
No adverse effect was observed in either trial except for hypoglycemic episodes in an insulin-treated MELAS
patient, which subsided by reducing the insulin dose.
Conclusions: Hydrogen-enriched water improves mitochondrial dysfunction in MM and inflammatory processes in
PM/DM. Less prominent effects with the double-blind trial compared to the open-label trial were likely due to a
lower amount of administered hydrogen and a shorter observation period, which implies a threshold effect or a
dose-response effect of hydrogen.
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Ohsawa and colleagues first reported an effect of hydro-
gen gas on cerebral infarction in June 2007 [1]. Effects
of hydrogen administered in the forms of inhaled gas,
drinking water, instillation, and intraperitoneal injection
have been reported for 31, 4, and 5 diseases in animal
models, cells, and humans, respectively [2]. Hydrogen
exhibits prominent effects especially on oxidative stress-
mediated diseases and inflammatory diseases in rodents.
Hydrogen scavenges hydroxyl radicals and less efficiently
peroxynitrite [1]. The radical-scavenging activities, how-
ever, are unlikely to be an exclusive mechanism, because
the amount of radical oxygen species generated in
rodents and humans is much more than the amount of
hydrogen molecules taken up by the body. Indeed, the
amount of hydrogen taken up by drinking hydrogen-
enriched water (HEW) is 100 or more times less than
that by inhaling 2% hydrogen gas, but drinking HEW
exhibits beneficial effects as good as or even better than
inhaling 2% hydrogen gas in rodents [2-4], which sug-
gests the lack of a simple dose-response effect. Our pre-
vious study on type 1 allergy also indicates that
hydrogen suppresses type 1 allergy by acting as a gas-
eous signal modulator not as a radical scavenger [5].
Effects of hydrogen in humans have been examined in
five studies. First, a randomized, double-blind, placebo-
controlled crossover study of 900 ml/day of HEW for 8
w e e k si n3 0p a t i e n t sw i t hd i a b e t e sm e l l i t u st y p e2
demonstrated significant decreases of electronegative
charge-modified LDL cholesterol, small dense LDL, and
urinary 8-isoprostanes [6]. Second, an open-label trial of
electrolyzed hydrogen-enriched hemodialysis solution in
9 patients for 4 months [7] and 21 patients for 6
months [8] showed significant decreases of systolic
blood pressure before and after dialysis, as well as of
plasma monocyte chemoattractant protein 1 and myelo-
peroxidase. Third, an open-label trial of 1.5-2.0 liters
per day of HEW for 8 weeks in 20 subjects with meta-
bolic syndrome exhibited a 39% increase of urinary
superoxide dismutase (SOD), a 43% decrease of urinary
thiobarbituric acid reactive substances (TBARS), an 8%
increase of high density lipoprotein (HDL)-cholesterol,
and a 13% decrease of total cholesterol/HDL-cholesterol
ratio [9]. Fourth, a randomized placebo-controlled study
of 1.5-2.2 liters/day of HEW for 6 weeks in 49 patients
receiving radiotherapy for malignant liver tumors
showed marked improvements of QOL scores [10]. As
the study was not blinded, subjective QOL scores
tended to be overestimated by a placebo effect, but
objective markers for oxidative stress were also signifi-
cantly decreased. Fifth, drip infusion of hydrogen-
enriched saline in combination with Edaravone, a clini-
cally approved radical scavenger for cerebral infarction,
for 7 days in 8 patients with brain stem infarction was
compared to 24 such patients receiving Edaravone alone
[11]. Although the study was not randomized and not
blinded, MRI markers of patients infused with hydrogen
showed significant improvements and accelerated
normalization.
Being prompted by the prominent effects of hydrogen
on inflammatory diseases and oxidative stress-mediated
diseases especially in rodents, we performed an open-
label trial of drinking 1.0 liter per day of HEW for 12
weeks in 14 patients with muscle diseases, and identified
improvement in four parameters: (i) a decrease of the
lactate-to-pyruvate ratio in mitochondrial myopathies
(MM) and progressive muscular dystrophy (PMD); (ii) a
decrease of serum matrix metalloproteinase-3 (MMP3)
in polymyositis/dermatomyositis (PM/DM), (iii) a
decrease of fasting glucose in PMD, and (iv) a decrease
of serum triglycerides in PM/DM. We then conducted a
randomized, double-blind, placebo-controlled, crossover
trial of 0.5 liter per day of HEW for 8 weeks in 12 MM
and 10 DM cases. We observed that HEW significantly
improved serum lactate in MM. In both studies, some
patients reported subjective improvement of fatigability,
diarrhea, and myalgia, but others reported floating sen-
sation and worsening of diarrhea. We observed no
objective improvement or worsening of clinical symp-
toms during each study. Our studies imply that HEW
improves clinical parameters in MM and PM/DM, but
0.5 liter/day for 8 weeks is likely to be insufficient to
demonstrate statistically significant effects.
Patients and methods
Patients
For the open-label trial, we recruited 5 patients with
PMD, 4 patients with PM/DM, and 5 patients with
MM. The PMD patients comprised 1 male with Miyoshi
myopathy and 4 females with limb girdle muscular dys-
trophy type 2B with an average age and SD of 50.4 ±
15.9 years (range 25 - 66). The PM/DM patients com-
prised 2 males and 2 females with an average age of
53.8 ± 24.8 years (range 29 - 83). All the PM/DM cases
were taking 5 - 10 mg of prednisolone per day and were
well controlled. The MM patients comprised 4 cases
with MELAS (2 males and 2 females with an average
age of 45.8 ± 12.3 years, range 37 - 64) and a 54-year-
old female with chronic progressive external ophthalmo-
plegia (CPEO).
For the randomized, double-blind, placebo-controlled,
crossover trial, we recruited 12 patients with MM and
10 patients with DM. The MM patients comprised 5
cases with MELAS (2 males and 3 females with an aver-
age age of 44.6 ± 17.6 years, range 20 - 65), as well as 7
cases with CPEO (3 males and 4 females with an aver-
age age of 49.1 ± 11.1 years, range 29 - 61). The DM
patients comprised 3 males and 7 females with an
Ito et al. Medical Gas Research 2011, 1:24
http://www.medicalgasresearch.com/content/1/1/24
Page 2 of 8average age of 49.6 ± 13.7 years (range 32 - 66). All the
DM patients were well controlled with 5 - 10 mg pre-
dnisolone per day. Three MM and three DM patients
participated in both trials. Both trials were approved by
the Ethical Review Board of the Aichi Medical Univer-
sity. Informed consent was obtained from each patient.
Protocols
We purchased 500 ml HEW or placebo water in aluminum
pouch from Blue Mercury Inc. (Tokyo, Japan). We mea-
sured hydrogen concentrations using an H2-N hydrogen
needle sensor attached to a PA2000 2-Channel Picoam-
meter (Unisense Science, Aarhus, Denmark). The hydrogen
concentrations were ~0.5 ppm (~31% saturation). We also
confirmed that hydrogen in placebo water was undetectable
with our system. For each trial, we instructed patients to
evacuate the air from the pouch and to close a plastic cap
tightly every time after they drink water to keep the hydro-
gen concentration as high as possible.
For the open-label trial, patients took 1.0 liter per day
of HEW in five to ten divided doses for 12 weeks. We
measured 18 serum and one urinary parameters and
recorded clinical symptoms at 0, 4, 8, 12, 16 weeks.
For the double-blind trial, patients took 0.5 liter per
day of HEW or placebo water in two to five divided
doses for 8 weeks. Between the 8-week trials with HEW
and placebo, we placed a 4-week washout period. We
measured 18 serum parameters and recorded clinical
symptoms at 0, 4, 8, 12, 16, 20, 24 weeks. In the double-
blind trial, we did not measure urinary 8-isoprostane
levels.
The data were statistically analyzed using one-way
repeated measures ANOVA for the open-label trial and
two-way repeated measures ANOVA for the double-
blind trial, both followed by the Bonferroni’s multiple
comparison test using Prism version 4.0c (Graphpad
Software, San Diego, CA).
Results
Open-label trial
Fourteen patients with PMD, PM/DM, and MM partici-
pated in the study and no patient dropped out of the
study. Patients took 1.0 liter of HEW for 12 weeks and
we measured 18 serum and one urinary parameters
every 4 weeks (Table 1). We observed no objective
improvement or worsening of clinical symptoms during
the study. All the patients reported increased micturi-
tion frequency. Two MELAS patients reported improve-
ment of fatigability, and another MELAS patient
complained mild occasional floating sensation. We esti-
mated statistical significance using one-way repeated
measures ANOVA analysis and detected five parameters
(Figure 1). Serum lactate-to-pyruvate (L/P) ratios of
MM patients were high before the study, and were
decreased during the study (Figure 1A). Serum L/P
ratios and fasting glucose levels of PMD patients were
elevated after the study, but the values were still within
normal ranges (Figures 1B and 1C). Serum MMP3 levels
of DM patients were decreased down to 72.9% of those
before HEW, which were again increased after the study
(Figure 1D). Serum triglyceride levels of DM patients
were elevated after the study (Figure 1E).
Randomized, double-blind, placebo-controlled, crossover
trial
Twelve MM and ten DM patients participated in the
study and no patient dropped out of the study. Patients
took 0.5 liter of HEW or placebo water for 8 weeks and
we measured 18 serum parameters every 4 weeks (Table
2). An MM patient reported increased micturition fre-
quency on HEW. A DM patient reported subjective
improvement of fatigability and diarrhea on HEW, but
an MM patient rather complained increased diarrhea at
first on HEW. Another DM patient reported an
improvement of myalgia on HEW. A MELAS patient
had hypoglycemic episodes only on HEW, but the epi-
sodes subsided after the insulin dose was decreased. We
observed no objective improvement or worsening of
clinical symptoms during the study. Two-way repeated
measures ANOVA analysis revealed that only serum lac-
tate levels were significantly decreased in MM by HEW
(Figure 2A). Temporal profiles of serum L/P ratios in
MM (Figure 2B) and of serum MMP3 levels in DM
(Figure 2C) also demonstrated favorable responses to
HEW but without statistical significance.
Discussion
We performed open-label and double-blind studies of
HEW on myopathic patients. In the open-label study,
we observed statistical significance of hydrogen effects
in four parameters: L/P ratios in MM and PMD; fasting
glucose in PMD; MMP3 in PM/DM; and triglycerides in
PM/DM (Figure 1). In the double-blind study, serum
lactate levels were significantly improved in MM. L/P
ratios in MM and MMP3 in DM were also improved
but without statistical significance (Figure 2). Small
numbers of participants in both the open-label and dou-
ble-blind studies might have failed to disclose statisti-
cally significant effects of HEW.
In MM, the mitochondrial electron transfer system
(mETS) is compromised by mutations in mitochondrial
DNA [12]. This results in a decreased influx of NADH
into mETS and elevates NADH levels in the cytoplasm,
which facilitates conversion of pyruvate to lactate by lac-
tate dehydrogenase. Thus, lactate and L/P ratio are use-
ful surrogate markers to estimate functions of mETS,
and are usually abnormally elevated in MM [12]. Defec-
tive mETS also causes leakage of electrons from
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Page 3 of 8Table 1 Open-label trial of HEW in 14 myopathic patients
Progressive muscular dystrophy (PMD) Polymyositis (PM)/Dermatomyositis (DM) Mitochondrial myopathies (MM)
Before 12 weeks After Before 12 weeks After Before 12 weeks After
CK (U/L) 3067 ± 1492 3419 ± 1610 3107 ± 2382 124 ± 31 180 ± 97 140 ± 86 187 ± 75 124 ± 47 156 ± 40
HbA1c (%) 5.25 ± 0.44 5.14 ± 0.31 5.16 ± 0.42 6.68 ± 1.61 6.70 ± 1.53 6.90 ± 2.03 7.40 ± 1.70 7.32 ± 1.48 7.38 ± 1.74
Fasting glucose (mmol/L) 5.52 ± 0.16** 5.51 ± 0.08** 5.82 ± 0.11** 7.66 ± 0.11 7.29 ± 1.57 7.69 ± 1.85 8.94 ± 3.24 9.31 ± 4.18 8.96 ± 3.19
Lactate
(mmol/L)
0.95 ± 0.34 1.15 ± 0.40 1.35 ± 0.40 1.42 ± 0.18 1.66 ± 0.32 1.30 ± 0.27 1.84 ± 0.50 1.87 ± 0.78 1.73 ± 0.65
L/P
ratio
12.1 ± 0.7* 10.7 ± 1.3* 13.6 ± 2.2* 13.1 ± 0.9 15.0 ± 3.2 12.7 ± 1.0 20.7 ± 2.9* 14.9 ± 3.5* 20.3 ± 3.1*
Creatinine (μmol/L) 34.8 ± 3.1 34.5 ± 6.9 34.7 ± 8.8 58.6 ± 13.7 56.3 ± 10.7 56.6 ± 14.1 48.8 ± 9.0 47.7 ± 9.7 48.6 ± 8.8
BUN (mmol/L) 4.74 ± 1.16 4.20 ± 0.60 4.21 ± 1.05 4.33 ± 0.71 4.11 ± 0.48 4.68 ± 0.74 5.28 ± 1.69 5.89 ± 1.09 5.00 ± 1.58
Uric acid (μmol/dL) 295 ± 46 315 ± 61 300 ± 30 319 ± 44 331 ± 71 329 ± 40 208 ± 50 220 ± 60 217 ± 45
Urinary 8-isoprostane
(ng/mg Cr)
303 ± 155 392 ± 173 n.d. 222 ± 88 237 ± 86 n.d. 274 ± 117 261 ± 59 n.d.
T-chol (mmol/L) 5.42 ± 0.99 5.74 ± 1.02 5.70 ± 0.81 5.28 ± 0.31 5.55 ± 0.93 5.97 ± 1.35 4.52 ± 0.75 4.53 ± 0.34 4.42 ± 0.77
LDL-chol (mmol/L) 3.30 ± 1.05 2.86 ± 1.46 2.99 ± 1.15 2.66 ± 0.28 3.21 ± 0.99 3.13 ± 1.02 2.44 ± 0.43 2.27 ± 0.44 2.22 ± 0.45
HDL-chol (mmol/L) 1.62 ± 0.21 1.49 ± 0.19 1.62 ± 0.18 2.01 ± 0.73 1.99 ± 0.76 2.02 ± 0.67 1.14 ± 0.79 1.03 ± 0.72 1.04 ± 0.69
Triglycerides (mmol/L) 1.31 ± 0.46 3.62 ± 4.83 3.07 ± 3.67 2.17 ± 0.63* 2.01 ± 1.21
* 3.09 ± 1.22* 0.78 ± 0.34 0.89 ± 0.45 0.73 ± 0.37
WBC (10
9/L) 5.30 ± 1.32 5.40 ± 1.12 4.80 ± 0.38 10.78 ± 2.08 8.35 ± 3.41 10.10 ± 0.17 5.12 ± 1.27 7.27 ± 2.29 5.93 ± 1.35
RBC (10
12/L) 4.17 ± 0.64 3.79 ± 0.42 3.87 ± 0.80 4.01 ± 0.62 4.34 ± 0.36 4.49 ± 0.45 4.33 ± 0.43 4.31 ± 0.78 4.35 ± 0.59
Platelets (10
9/L) 262 ± 42 260 ± 33 270 ± 20 337 ± 123 265 ± 82 270 ± 65 215 ± 25 207 ± 28 217 ± 25
Hematocrit 0.375 ± 0.040 0.374 ± 0.038 0.407 ± 0.055 0.337 ± 0.069 0.376 ± 0.041 0.395 ± 0.045 0.381 ± 0.036 0.370 ± 0.047 0.378 ± 0.038
MMP3 (ng/ml) n.d. n.d. n.d. 307.8 ± 59.1* 224.3 ± 53.4* 283.3 ± 77.6* n.d. n.d. n.d.
IgG (mg/dl) n.d. n.d. n.d. 1343 ± 470 1396 ± 550 1429 ± 581 n.d. n.d. n.d.
Values represent mean ± SD. n.d., not determined. *p < 0.05 and **p < 0.005 by one-way repeated measures ANOVA.
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Figure 1 Temporal profiles of four parameters that demonstrate statistical significance by one-way repeated measures ANOVA in the
open-label trial. Ratios of serum lactate/pyruvate (L/P) in 5 mitochondrial myopathies (MM) patients (A) and 4 progressive muscular dystrophy
(PMD) patients (B). Note abnormally high L/P ratios in MM patients. (C) Fasting glucose in 4 PMD patients. (D) Serum MMP3 in 5 Polymyositis
(PM)/Dermatomyositis (DM) patients. (E) Serum triglycerides in 4 PMD patients. Twelve weeks on HEW are indicated by a box in each panel.
Means and SD are plotted. Statistically different values by the Bonferroni’s multiple comparison test are indicated by ‘a’ and ‘b’ with *p < 0.05
and **p < 0.01. Bonferroni’s test reveal no statistical difference between any two values in (D) and (E). Broken lines show a normal range of
each parameter.
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Page 5 of 8mitochondrial inner membranes and increases produc-
tion of reactive oxygen species (ROS), which further
damages mETS [13,14]. Reduction of the L/P ratios in
the open-label and double-blind studies suggests that
hydrogen alleviates mETS dysfunction in MM either by
scavenging ROS or by yet unidentified signaling
mechanisms.
MMP3 belongs to a family of calcium-dependent zinc
proteinases induced by cytokines and secreted by
inflammatory cells. MMPs enhance T-cell migration and
adhesion, and also degrade the extracellular matrix pro-
teins [15]. MMP3 is increased in a fraction of DM
patients [16]. MMP3 may facilitate lymphocyte adhesion
and enhance T-cell-mediated cytotoxicity by degrading
extracellular matrix proteins in DM. Hydrogen
improved serum MMP3 levels in the open-label and
double-blind studies, which is expected to ameliorate
pathogenic inflammatory processes that culminates in
muscle fiber destruction.
We observed less prominent effects with the double-
blind study compared to the open-label study. The lack
of statistically significance in the double-blind study is
possibly due to a lower amount of HEW (1.0 vs. 0.5
liter per day) and to a shorter observation period (12 vs.
8 weeks). In the open-label study, drinking 1.0 liter of
HEW was not readily accommodated by most myo-
pathic patients. Hydrogen does not show simple dose-
response relationship in rodents [2-4], and ad libitum
administration of even 5%-saturated HEW markedly
attenuates development of Parkinson’s disease in mice
[17]. We thus reduced the amount of hydrogen to 0.5
liter in the double-blind trial, and also shortened the
observation period to minimize the burden on the parti-
cipants. This, however, might have masked effects of
HEW. Indeed, when we compare studies of diabetes
mellitus type 2 [6], the current open-label trial, and
metabolic syndrome [9], the participants took 0.9, 1.0,
and 1.5-2.0 liters of HEW, respectively. Ratios of total
cholesterol/HDL-cholesterol are available at 8 weeks in
all the studies, and are changed to 103.8%, 98.6%, and
95.8%, respectively, of those before hydrogen administra-
tion, which is in accordance with a dose-response effect
of HEW. Additionally, among the two previous studies
[6,9] and the current open-label and double-blind stu-
dies, the most prominent effects are observed with 1.5-
2.0 liters of HEW. As drinking a large amount of HEW
is not easily accommodated by most patients especially
in winter, a threshold effect and/or a dose-response
effect should be further elaborated for each pathological
state.
Conclusions
HEW is effective for mitochondrial dysfunction in MM
and inflammatory processes in DM. Hydrogen may have
Table 2 Randomized, double-blind, placebo-controlled, crossover trial of HEW in 10 DM and 12 MM patients
Dermatomyositis (DM) Mitochondrial myopathies (MM)
Hydrogen water Placebo water Hydrogen water Placebo water
0 week 8 weeks 0 week 8 weeks 0 week 8 weeks 0 week 8 weeks
CK (U/L) 88.7 ± 24.3 106.1 ± 88.2 93.5 ± 45.0 99.5 ± 86.7 165 ± 86.6 120 ± 55.5 142.0 ± 69.4 221 ± 235
HbA1c (%) 6.23 ± 1.28 6.34 ± 1.55 6.27 ± 1.44 6.16 ± 1.28 6.09 ± 0.94 6.12 ± 1.05 6.06 ± 1.22 6.06 ± 1.02
Fasting glucose (mmol/L) 8.27 ± 3.62 7.81 ± 2.91 6.70 ± 2.11 6.48 ± 1.90 6.05 ± 1.43 5.67 ± 1.99 6.02 ± 1.46 6.11 ± 1.69
Lactate (mmol/L) 1.93 ± 0.78 1.81 ± 0.87 1.80 ± 0.89 1.65 ± 0.77 1.76 ± 0.67* 1.61 ± 0.48* 1.49 ± 0.49* 1.70 ± 0.57*
L/P ratio 13.1 ± 6.0 11.5 ± 2.6 12.1 ± 2.88 15.2 ± 8.3 18.7 ± 8.8 17.9 ± 7.7 7.12 ± 13.4 17.7 ± 8.6
Creatinine (μmol/L) 59.1 ± 15.6 59.1 ± 13.6 58.3 ± 15.0 59.0 ± 19.7 53.6 ± 18.3 52.0 ± 17.4 54.8 ± 20.3 57.5 ± 22.3
BUN (mmol/L) 5.36 ± 1.48 4.82 ± 1.57 5.78 ± 1.71 4.86 ± 1.56 6.08 ± 2.09 5.39 ± 1.54 6.24 ± 1.46 6.34 ± 2.76
Uric Acid (μmol/dL) 303 ± 88 320 ± 68 313 ± 75 321 ± 83 413 ± 316 375 ± 229 447 ± 387 408 ± 284
T-chol (mmol/L) 5.23 ± 0.78 5.15 ± 0.85 5.21 ± 0.61 4.95 ± 0.92 4.61 ± 0.78 4.80 ± 0.57 4.69 ± 0.78 4.68 ± 0.71
LDL-chol (mmol/L) 3.06 ± 0.82 2.93 ± 0.75 2.97 ± 0.80 3.03 ± 0.84 2.69 ± 0.68 2.82 ± 0.58 2.73 ± 0.67 2.79 ± 0.60
HDL-chol (mmol/L) 1.59 ± 0.48 1.56 ± 0.36 1.53 ± 0.47 1.43 ± 0.48 1.47 ± 0.04 1.55 ± 0.34 1.52 ± 0.34 1.45 ± 0.35
Triglycerides (mmol/L) 1.54 ± 0.65 1.83 ± 0.76 1.86 ± 0.80 1.85 ± 0.48 1.16 ± 0.58 0.92 ± 0.35 0.97 ± 0.36 1.02 ± 0.49
WBC (10
9/L) 11.7 ± 6.4 10.9 ± 3.1 9.66 ± 2.68 11.2 ± 4.7 5.5 ± 0.1 5.7 ± 1.8 5.81 ± 1.78 5.8 ± 1.9
RBC (10
12/L) 4.28 ± 0.05 4.32 ± 0.35 4.37 ± 0.44 4.35 ± 0.44 4.15 ± 0.04 4.17 ± 0.61 4.26 ± 0.67 4.15 ± 0.56
Platelets (10
9/L) 271 ± 10 302 ± 69 306 ± 54 312 ± 79 203 ± 40 214 ± 44 216 ± 48 225 ± 50
Hematocrit (%) 0.380 ± 0.004 0.384 ± 0.040 0.392 ± 0.052 0.391 ± 0.047 0.373 ± 0.004 0.378 ± 0.060 0.386 ± 0.063 0.376 ± 0.058
MMP3 (ng/ml) 245 ± 122 232 ± 84.1 217 ± 93.5 221 ± 112 n.d. n.d. n.d. n.d.
IgG (mg/dl) 1211 ± 357 1244 ± 305 1202 ± 340 1282 ± 353 n.d. n.d. n.d. n.d.
Values represent mean ± SD. n.d., not determined. *p < 0.05 by two-way repeated measures ANOVA.
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or more per day of HEW is likely to be required to
exert beneficial effects.
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